In low-risk MDS patients with symptomatic anemia and a low EPO level, how does the presence of a high-frequency SF3B1 mutation influence your first-line choice between an ESA and luspatercept?
Does the absence of ringed sideroblasts on bone marrow biopsy (despite the SF3B1 mutation) change your approach?
Community PollStarted
In low-risk, transfusion-dependent MDS patients with a SF3B1 mutation and low serum EPO level, which first-line treatment would you choose?
15 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · UC San Diego Health
Answered on
I would consider the SF3B1 mutation to be the relevant biomarker for the selection of frontline therapy (namely luspatercept) in this case. The correlation between SF3B1 mutations and the presence of ring sideroblasts in MDS is strong but not perfect. This could be for a variety of reasons, the most...
Join for free or sign in to see the full answer